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Abstract 
BACKGROUND: Skin cancer is an uncommon cause of skull invasion, dural infiltration and brain parenchyma 
involvement.  
CASE REPORT: We report on a series of three elderly patients who presented with squamous cell carcinoma of 
the scalp with skull bone and cerebral invasion and discuss the diagnostic and therapeutic challenges.  
CONCLUSION: A major factor of delayed diagnosis of this potentially life-threatening skin cancer feature is 
patients’ neglecting. 
 
 
 
 
 
 
 
 
 
Introduction 
 
Malignant skin tumours of the scalp with skull 
invasion, dural infiltration and brain involvement are 
uncommon. However, in advanced cases, skin cancer 
may be associated with infiltration of the skull bone 
and even the brain. In a 10-year retrospective 
analysis, Brunner et al. (2017) analysed 62 patients 
with malignant craniofacial skin tumours. Brain 
invasion, surgical margin involvement, and dural 
margin involvement were the factors that significantly 
reduce survival. They concluded that the resection of 
bone is a reasonable surgical option in the treatment 
of patients with advanced skin cancer of the face and 
scalp [1]. In a retrospective study of 25 patients with 
aggressive squamous cell carcinoma (SCC) of the 
scalp from Catania (Italy) a multidisciplinary approach 
achieved a complete response in 22 patients with a 
follow-up of seven years. Three patients died from 
other causes not related to the cutaneous malignancy 
[2]. 
 
 
Case Reports 
 
Case 1 
An 80-year-old male patient presented a fast-
growing exophytic tumour parietal right, measuring 8 x 
7 cm. A keratoacanthoma or keratoacanthoma-like 
SCC was suspected (Figure 1, A and B). He had 
several comorbidities including dementia, arterial 
hypertension, glaucoma and atrial fibrillation. Five 
years ago, another SCC had been removed surgically. 
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He was treated with rivaroxaban and anti-
hypertensive drugs. 
Lymph node sonography and chest-X-ray 
were unremarkable. Computerised tomography (CT) 
and magnetic resonance imaging (MRI) of the head 
demonstrated an osteolytic defect of the skull 
measuring 2.6 cm in diameter with the involvement of 
the tabula interna. The MRI suggested a tumour 
infiltration of the sinus sagittalis and the dura mater 
(Figure 1, C and D). The surgical situs demonstrated 
an exophytic, the skull infiltrating tumour with a 
pulsation at the bottom of the skull defect (Figure 1C). 
In association with the neurosurgeon, it was decided 
to perform a temporary closure with a meshed graft. 
Histopathology confirmed the diagnosis of an SCC, 
pT3, G2. Imaging techniques excluded a metastatic 
spread leading to the final tumour stage of pT3 cN0 
cM0, G2, stage III. 
Because of the R1-resection status, the 
patient was presented to the interdisciplinary tumour 
board. Adjuvant radiotherapy and complete 
neurosurgical excision of the tumour were discussed. 
Both methods bear a mortality risk. After consultation 
with the family, and because of dementia, palliative 
treatment was initiated.   
 
Figure 1: Patient #1 with SCC; A) and B) clinical presentation of the 
tumour; C) Surgical situs with infiltration of the skull; D) MRI scan 
with osteolytic skull lesion; E) and F) CT scan with skull penetrating 
the tumour 
 
Case 2 
An 83-year old female patient presented with 
a long-standing occipital scalp tumour, that was 
hidden by hair and crusts. The lesion developed over 
several years. Due to recent bleeding, the patient had 
been referred to our department (Figure 2A).  
She was living in a nursing home. Her 
medical history was positive for arterial hypertension, 
depression and diabetes type II, which were 
pharmacologically treated. A diagnostic skin biopsy 
revealed an SCC, G2. On CT, a 42 x 53 mm large full-
thickness skull defect was noted (Figure 2, B and D). 
By imaging techniques, there was no evidence of a 
metastatic spread. In association with the 
neurosurgeon, complete surgical removal had been 
discussed but was denied by the patient and her 
family. Palliative care was initiated. The patient was 
lost to follow-up. 
 
Figure 2: Patient # 2; A) Clinical presentation of the SCC; C) to D) 
CT scan with a large osteolytic skull lesion due to tumour infiltration 
 
Case 3 
A 67-year-old man presented to the 
emergency room with very large bleeding, the 
ulcerated, malodorous, exophytic tumour of the scalp, 
infested by maggots, that was slowly growing over 
more than two years. His medical history was 
remarkable for chronic alcohol abuse. He had no 
medical drug therapy. 
We observed cauliflower-like exophytic 
growth with partial necrosis and discharged 
measuring 23 cm x 12 cm x 2.4 cm localised in the 
midline of the frontal skull (Figure 3A). There were 
neither clinical signs of tumour spread to regional 
lymph nodes nor any neurological impairment. A 
diagnostic biopsy was taken that confirmed the 
diagnosis of a tricholemmal SCC (Broders grade 3) 
(Figure 3D). Routine laboratory demonstrated 
anaemia and hypoproteinemia: erythrocyte count 3.1 
Tpt/L (normal range 4.6-6.2), haemoglobin 6.4 mmol/L 
(normal range 8.6-12.1), and serum protein 43.3 g/L 
(normal range 60-85). 
Microbial swabs from the tumour surface 
revealed Proteus mirabilis, Alcaligens faecalis, and 
beta-hemolytic streptococci that were sensitive to 
levofloxacin. 
Staging with thoracic X-ray, lymph node 
sonography, and cranial CT did not show any 
metastases. Cranial CT, MRI, and gadolinium-
enhanced vascular MRI disclosed parietal parasagittal 
cranial tumor invasion with a continuous extension to 
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the meninges on the left side with infiltration (3.5 cm x 
3.7 cm) and partial closure of the medial part of the 
superior sinus sagittalis (remaining open lumen 2.4 
cm) (Figure 3, B and C). 
After good ulcer care and initiation of 
intravenous levofloxacin therapy (2 x 250 mg/day), we 
performed a debulking surgery in association with the 
neurosurgeon with lateral safety margins of 2 cm 
down to the skull bone. During surgery, a large full-
thickness skull bone defect in the neighbourhood of 
the sinus sagittalis was visible.  
The defect was covered by oxygenised 
regenerated cellulosis (Tabotamp, Johnson & 
Johnson—Ethicon) and split-thickness skin meshes 
graft transplant (Figure 3, E and F). 
There was an uneventful postoperative 
course, and the patient could leave the intensive care 
unit after 24 hours, but the transplant was lost after 
seven days. A second surgery with complete 
debridement of the defect and thinning of the outer 
tabula of the skull bone by a larger rose drill was 
performed. After that, a smaller rose drill was used to 
make penetrations into the spongiosa to reach diploe 
veins for transplant nutrition. The whole area was 
covered with a dermal template of porcine collagen 
(mediCipio, V-CARE Biomedical, Leipzig). Split skin 
was obtained from the abdomen, meshed 1:1.5, and 
transplanted onto the dermal template. A light 
protective helmet was provided to support 
mobilisation. The patient was re-staged after two 
months when a collateral circulation around the 
thrombosed sagittal sinus was evident. We planned a 
neuro-vascular surgery for complete removal of the 
remaining tumour. One week before the scheduled 
operation, he died in a traffic accident. 
 
Figure 3: Patient #3: a, cauliflower-like exophytic growth with partial 
necrosis and discharged measuring 23 cm x 12 cm x 2.4 cm 
localised in the midline of the frontal skull; b, c, Cranial CT, MRI, 
and gadolinium-enhanced vascular MRI disclosed parietal 
parasagittal cranial tumor invasion with a continuous extension to 
the meninges on the left side with infiltration (3.5 cm x 3.7 cm) and 
partial closure of the medial part of the superior sinus sagittalis 
(remaining open lumen 2.4 cm); d, A diagnostic biopsy was taken 
that confirmed the diagnosis of a tricholemmal SCC (Broders grade 
3); e, f, The defect was covered by oxygenised regenerated 
cellulosis (Tabotamp, Johnson & Johnson—Ethicon) and split-
thickness skin meshes graft transplant 
Discussion 
 
Skull and cranial invasion are rare among 
cutaneous malignancies. Cancer that has been most 
often reported to cause this rare but potentially life-
threating complication is SCC [2], [3], [4].
 
 
Other tumours with a potential of cranial 
infiltration are adenoid carcinoma, basal cell 
carcinoma, and cutaneous melanoma [5], [6], [7]. 
We presented three patients (one female and 
three males) with full-thickness skull bone penetration 
by SCC and intracranial extension. The main cause 
for the late diagnosis and treatment was the 
neglection of the tumours by the patients. But GP’s, 
nurses and family members were unable to overcome 
this disadvantage. Interestingly, none of these 
patients presented with neurological symptoms. This 
argues for a slow process of intracranial tumour 
invasion. 
The differential diagnosis includes 
metastases. The most common site of metastases is 
the bony skull, while dural metastasis occurs less 
frequently and may mimic subdural hematoma [8]. 
The treatment of these advanced SSC’s 
should be multidisciplinary with dermatology, 
neurosurgery, radiotherapy, and rehabilitative 
medicine. In the case of dura and brain invasion, the 
mortality is increased [1], [2]. Newer pharmaceutical 
treatment options include epidermal growth factor 
receptor inhibitors such as cetuximab-alone or in 
combination with radiotherapy-and immune 
checkpoint inhibitors like cemiplimab (anti-
programmed death-1) [9], [10], [11]. The response 
rate in real life, however, is less than 50% and short-
lived. Surgery remains the cornerstone of treatment 
[1], [2], [10].  
In conclusion, in addition to metastases into 
the brain and the meninges, nonmelanoma skin 
cancer can cause other types of cancer involvement 
by local bone infiltration and perineural invasion. 
Often, a multidisciplinary approach for diagnosis and 
treatment of these cancers will be needed. 
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